

**WHAT IS CLAIMED IS:**

5           1. A stable suspension of a biologically active protein suited for aerosol delivery to the respiratory tract of a patient in need of treatment comprising particles of said protein suspended in ethanol.

          2. A stable suspension according to claim 1 wherein said ethanol is  
10 substantially anhydrous.

          3. A stable suspension according to claim 1 wherein said ethanol contains less than 5% water.

15           4. A stable suspension according to claim 1 wherein said ethanol contains less than 3% water.


          5. A stable suspension according to claim 1 wherein said biologically active protein is selected from the group comprising enzymes, antibodies,  
20 antigens, hormones and cytokines.

          6. A stable suspension according to claim 5 wherein said therapeutically active protein is a hormone.

25           7. A stable suspension according to claim 6 wherein said therapeutically active protein is insulin.

          8. A stable suspension according to claim 5 wherein said therapeutically active protein is a cytokine.  
30

          9. A stable suspension according to claim 5 wherein said therapeutically active protein is Factor VIII.



10. A stable suspension according to claim 1 wherein the particle size of said protein is from about 0.01  $\mu$  to about 10.0  $\mu$ .

5 11. A stable suspension according to claim 10 wherein the particle size of said protein is from about 5.0  $\mu$  to about 10.0  $\mu$ .

12. A stable suspension according to claim 11 wherein the particle size of said protein is from about 0.01  $\mu$  to about 3.0  $\mu$ .

10 13. A stable suspension according to claim 1 wherein said suspension contains up to 20% V/V of a formulation additive.

14. A stable suspension according to claim 13 wherein said suspension formulation additive is selected from the group consisting of  
15 glycerol, propylene glycol and polyethylene glycol.

15. A stable suspension according to claim 1 wherein said suspension contains from about 0.5% to about 5.0% of a pharmaceutically acceptable excipient.

20 16. A stable suspension of insulin useful for aerosol delivery to the lungs of a patient in need of treatment comprising particles of a pharmaceutically effective amount of insulin suspended in ethanol.

25 17. A stable suspension according to claim 16 wherein said insulin is present in the suspension at a concentration of from about 1.0 mg/ml to about 200.0 mg/ml of suspension.

30 18. A stable suspension according to claim 16 wherein the particle size of said insulin is from about 0.01  $\mu$  to about 5.0  $\mu$ .

19. A stable suspension according to claim 16 wherein said suspension contains up to 20% V/V of a formulation additive.

20. A stable suspension according to claim 19 wherein said suspension formulation additive is selected from the group consisting of glycerol, propylene glycol and polyethylene glycol.

5           21. A stable suspension according to claim 16 wherein said suspension contains from about 0.5% to about 5.0% of a pharmaceutically acceptable excipient.

10           22. A method of delivering a therapeutically effective amount of a protein to the respiratory tract of a patient in need of treatment which comprises producing an aerosol of a stable liquid suspension of said protein using an electrostatic spraying means wherein said liquid suspension comprises particles of said protein suspended in ethanol.

15           23. A method according to claim 22 wherein said protein is selected from the group comprising enzymes, antibodies, antigens, hormones and cytokines.

20           24. A method according to claim 23 wherein said therapeutically active protein is a hormone.

25           25. A method according to claim 24 wherein said hormone is insulin.

26           26. A method according to claim 23 wherein said protein is a cytokine.

27           27. A method according to claim 26 wherein said cytokine is Factor VIII.

30           28. A method according to claim 22 wherein the particle size of said protein is from about 0.01  $\mu$  to about 10.0  $\mu$ .

29. A method according to claim 28 wherein the particle size of said protein is from about 5.0  $\mu$  to about 10.0  $\mu$ .

30. A method according to claim 29 wherein the particle size of said protein is from about 0.01  $\mu$  to about 3.0  $\mu$ .

31. A stable suspension according to claim 22 wherein said  
5 suspension contains up to 20% V/V of a formulation additive.

32. A stable suspension according to claim 31 wherein said  
suspension formulation additive is selected from the group consisting of  
glycerol, propylene glycol and polyethylene glycol.  
10

33. A stable suspension according to claim 22 wherein said  
suspension contains from about 0.5% to about 5.0% of a pharmaceutically  
acceptable excipient.  
15